PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |

darifenacin

  • darifenacin is a weak inhibitor of CYP2D6.
  • darifenacin is neither an inhibitor or inducer of CYP2C9.
  • darifenacin did not meet the criteria of being an inhibitor or inducer of CYP3A.
  • CYP2C9CYP2D6CYP3A
    Weak inhibitorsamiodarone [1]
    cimetidine [2]
    co-trimoxazole [3]
    disulfiram [4]
    echinacea [5]
    fluvastatin [6]
    fluvoxamine [7]
    ketoconazole [8]
    lovastatin [1]
    metronidazole [9]
    sertraline [10]
    simvastatin [1]
    sulfadiazine [11]
    voriconazole [12]
    zafirlukast [a]
    amiodarone [13]
    amitriptyline [14]
    aspirin [15]
    celecoxib [16]
    cimetidine [17]
    darifenacin [b]
    desvenlafaxine [18]
    diltiazem [19]
    diphenhydramine [20]
    escitalopram [21]
    felodipine [22]
    fluvoxamine [23]
    gefitinib [24]
    hydralazine [25]
    imatinib [26]
    interferon alpha-2b [27]
    ketoconazole [28]
    methadone [29]
    metoprolol [30]
    nortriptyline [31]
    oral contraceptives [32]
    oxprenolol [30]
    pindolol [30]
    propranolol [30]
    ranitidine [33]
    risperidone [34]
    ritonavir [35]
    saw palmetto [36]
    sertraline [37]
    timolol [30]
    venlafaxine [38]
    alprazolam [39]
    amiodarone [40]
    aspirin [15]
    azithromycin [41]
    bicalutamide [42]
    cimetidine [43]
    co-trimoxazole [44]
    cyclosporine [45]
    fluvoxamine [46]
    isoniazid [47]
    maraviroc [48]
    oral contraceptives [49]
    ranitidine [50]
    roxithromycin [51]
    simvastatin [52]
    No apparent change in clearanceamodiaquine [53]
    darifenacin [a]
    modafinil [54]
    omeprazole [55]
    prednisone [56]
    St John's wort [57]
    amodiaquine [53]
    dexamethasone [58]
    echinacea [5]
    ginko-biloba [59]
    maraviroc [60]
    omeprazole [61]
    smoking [62]
    cimetidine [63]
    echinacea [5]
    finasteride [64]
    fluoxetine [46]
    gatifloxacin [65]
    methylprednisolone [66]
    paroxetine [67]
    pioglitazone [52]
    saw palmetto [36]
    sertraline [68]
    tenofovir [44]
    tipranavir/ritonavir [69]
    venlafaxine [70]
    Criteria not metcapecitabine [71]
    itraconazole [72]
    chloroquine [73]
    citalopram [74]
    clomipramine [75]
    disulfiram [76]
    grapefuit juice [77]
    hydroxychloroquine [78]
    orange juice [77]
    propoxyphene [79]
    verapamil [80]
    amprenavir [c]
    buspirone [c]
    ciprofloxacin [d] [81]
    citalopram [c]
    darifenacin [c]
    darunavir/ritonavir [d] [c]
    dasatinib [c]
    efavirenze
    erlotinib [c]
    fosamprenavir [d] [82]
    nevirapine [c]
    nilotinib [c]
    omeprazole [c]
    oxcarbazepine [c]
    phenobarbitone [e] [83]
    propoxyphene [84]
    rifabutin [c]

    Footnotes and References

    a.assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).
    b.systemic preparations not available in Australia or New Zealand.
    c.clinical PK interaction studies referred to in product information.
    d.likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).
    e.likely to be a major inducer based on subjective evaluation (≥ 2-fold decrease in AUC or ≥ 50% increase in clearance of in vivo CYP probe).
    1.Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. European Journal of Clinical Pharmacology 2006; 62: 291-96.[PubMed]
    2.Back DJ, Tjia J, Monig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. European Journal of Clinical Pharmacology 1988; 34: 157-63.[PubMed]
    3.Miners JO, Wing LMH. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. British Journal of Clinical Pharmacology 1985; 20: 482-85.[PubMed]
    4.Svendsen TL, Kristensen MB, Hansen JM, Skovsted L. The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. European Journal of Clinical Pharmacology 1976; 5-6: 439-41.[PubMed]
    5.Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clinical Pharmacology & Therapeutics 2004; 75: 89-100.[PubMed]
    6.Kim MJ, Nafziger AN, Kashuba ADM, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. European Journal of Clinical Pharmacology 2006; 62: 431-36.[PubMed]
    7.Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clinical Pharmacology & Therapeutics 2001; 69: 41-47.[PubMed]
    8.Krishnaiah YSR, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. British Journal of Clinical Pharmacology 1994; 37: 205-07.[PubMed]
    9.O'Reilly R. The stereoselective interaction of warfarin and metronidazole in man. New England Journal of Medicine 1976; 295: 354-57.[PubMed]
    10.Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clinical Pharmacokinetics 1997; 32: 31-36.[PubMed]
    11.Hansen JM, Kampmann JP, Siersbaeknielsen K, Lumholtz IB, Arroe M, Abildgaard U, Skovsted L. The effect of different sulfonamides on phenytoin metabolism in man. Acta Medica Scandinavica 1979: 106-10.[PubMed]
    12.Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. British Journal of Clinical Pharmacology 2003; 56: 37-44.[PubMed]
    13.Fukumoto K, Kobayashi T, Tachibana K, Kat R, Tanaka K, Komamura K, Kamakura S, Kitakaze M, Ueno K. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 2006; 21: 501-05.[PubMed]
    14.Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzierperey M, Koeb L, Monney C, Woggon B. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Therapeutic Drug Monitoring 1992; 14: 1-8.[PubMed]
    15.Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics 2003; 73: 264-71.[PubMed]
    16.Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical Pharmacology & Therapeutics 2003; 74: 130-37.[PubMed]
    17.Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clinical Pharmacology & Therapeutics 1987; 42: 278-82.[PubMed]
    18.Patroneva A, Connolly SM, Fatato P, Pedersen R, Jiang Q, Paul J, Guico-Pabia C, Isler JA, Burczynski ME, Nichols AI. An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects. Drug Metabolism and Disposition 2008; 36: 2484-91.[PubMed]
    19.Tateishi T, Nakashima H, Shitou T, Kumagai Y, Ohashi K, Hosoda S, Ebihara A. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. European Journal of Clinical Pharmacology 1989; 36: 67-70.[PubMed]
    20.Sharma A, Pibarot P, Pilote S, Dumesnil JG, Arsenault M, Belanger PM, Meibohm B, Hamelin BA. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. Journal of Pharmacology and Experimental Therapeutics 2005; 313: 1172-81.[PubMed]
    21.Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of Clinical Psychopharmacology 2007; 27: 28-34.[PubMed]
    22.Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. European Journal of Clinical Pharmacology 1987; 31: 575-78.[PubMed]
    23.Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. Journal of Clinical Psychopharmacology 1999; 19: 155-63.[PubMed]
    24.Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical Pharmacokinetics 2005; 44: 1067-81.[PubMed]
    25.Jack DB, Kendall MJ, Dean S, Laugher SJ, Zaman R, Tenneson ME. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharmaceutics & Drug Disposition 1982; 3: 47-54.[PubMed]
    26.Wang YF, Zhou L, Dutreix C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQP, Schran H, Shen ZX. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. British Journal of Clinical Pharmacology 2008; 65: 885-92.[PubMed]
    27.Islam M, Frye RF, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. Differential Effect of IFNalpha-2b on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and Its Modulation by Other Drugs. Clinical Cancer Research 2002; 8: 2480-87.[PubMed]
    28.Atiba JO, Blaschke TF, Wilkinson GR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. British Journal of Clinical Pharmacology 1989; 28: 161-65.[PubMed]
    29.Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. British Journal of Clinical Pharmacology 1993; 35: 30-34.[PubMed]
    30.Kallio J, Huupponen R, Seppala M, Sako E, Iisalo E. The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. British Journal of Clinical Pharmacology 1990; 30: 638-43.[PubMed]
    31.Solai LK, Pollock BG, Mulsant BH, Frye RF, Miller MD, Sweet RA, Kirshner M, Sorisio D, Begley A, Reynolds CF. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of Clinical Psychopharmacology 2002; 22: 481-86.[PubMed]
    32.Kendall MJ, Quarterman CP, Jack DB, Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. British Journal of Clinical Pharmacology 1982; 14: 120-22.[PubMed]
    33.Kelly JG, Salem SAM, Kinney CD, Shanks RG, McDevitt DG. Effects of ranitidine on the disposition of metoprolol. British Journal of Clinical Pharmacology 1985; 19: 219-24.[PubMed]
    34.Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P. Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Therapeutic Drug Monitoring 2001; 23: 228-31.[PubMed]
    35.Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clinical Pharmacology & Therapeutics 2005; 78: 664-74.[PubMed]
    36.Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clinical Pharmacology & Therapeutics 2003; 74: 536-42.[PubMed]
    37.Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Journal of Clinical Psychopharmacology 1997; 17: 284-91.[PubMed]
    38.Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. Journal of Clinical Pharmacology 2001; 41: 443-51.[PubMed]
    39.Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. Journal of Clinical Pharmacology 1993; 33: 1104-09.[PubMed]
    40.Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clinical Pharmacology & Therapeutics 2007; 81: 679-84.[PubMed]
    41.Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel-Forschung/Drug Research 1996; 46: 213-17.[PubMed]
    42.Cockshott ID. Bicalutamide - Clinical pharmacokinetics and metabolism. Clinical Pharmacokinetics 2004; 43: 855-78.[PubMed]
    43.Somogyi A, Muirhead M. Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics 1987; 12: 321-66.[PubMed]
    44.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 47-53.[PubMed]
    45.Li G, Treiber G, Meinshausen J, Wolf J, Werringloer J, Klotz U. Is cyclosporin A an inhibitor of drug metabolism? British Journal of Clinical Pharmacology 1990; 30: 71-77.[PubMed]
    46.Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of Clinical Pharmacology 2003; 43: 1274-82.[PubMed]
    47.Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. British Journal of Clinical Pharmacology 1983; 16: 743-46.[PubMed]
    48.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 19-26.[PubMed]
    49.Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1 '-hydroxylation. British Journal of Clinical Pharmacology 2000; 50: 333-37.[PubMed]
    50.Elliott P, Dundee JW, Elwood RJ, Collier PS. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. European Journal of Anaesthesiology 1984; 1: 245-51.[PubMed]
    51.Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. European Journal of Clinical Pharmacology 1994; 46: 551-55.[PubMed]
    52.Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC, Rogers JD. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. Journal of Clinical Pharmacology 2001; 41: 573-81.[PubMed]
    53.Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European Journal of Clinical Pharmacology 2006; 62: 539-46.[PubMed]
    54.Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. Journal of Clinical Pharmacology 2002; 42: 205-14.[PubMed]
    55.Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. British Journal of Clinical Pharmacology 1993; 36: 380-82.[PubMed]
    56.Breimer DD, Zilly W, Richter E. Influence of corticosteroid on hexobarbital and tolbutamide disposition. Clinical Pharmacology & Therapeutics 1978; 24: 208-12.[PubMed]
    57.Wang ZQ, Gorski C, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology & Therapeutics 2001; 70: 317-26.[PubMed]
    58.McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clinical Pharmacology & Therapeutics 2000; 68: 356-66.[PubMed]
    59.Markowitz JS, Donovan JL, DeVane L, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. Journal of Clinical Psychopharmacology 2003; 23: 576-81.[PubMed]
    60.Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 5-18.[PubMed]
    61.Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clinical Pharmacology & Therapeutics 1996; 60: 396-404.[PubMed]
    62.Yue QY, Tomson T, Sawe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4: 193-98.[PubMed]
    63.Greenblatt DJ, Locniskar A, Scavone JM, Blyden GT, Ochs HR, Harmatz JS, Shader RI. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesthesia and Analgesia 1986; 65: 176-80.[PubMed]
    64.Yasumori T, Narita H, Matsuda T, Takubo T, Ogawa M, Ishii M, Hara K, Ishii Y, Okuyama K, Fujimoto G, Ochiai H, Kano A, Hasegawa S, Sato K, Taniguchi T. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese. European Journal of Clinical Pharmacology 2006; 62: 939-46.[PubMed]
    65.Grasela DM, LaCreta FP, Kollia GD, Randall DM, Uderman HD. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Pharmacotherapy 2000; 20: 330-35.[PubMed]
    66.Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivisto KT. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. European Journal of Clinical Pharmacology 2001; 57: 457-60.[PubMed]
    67.Calvo G, García-Gea C, Luque A, Morte A, Dal-Ré R, Barbanoj M. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24: 268-76.[PubMed]
    68.Hassan PC, Sproule BA, Naranjo CA, Herrmann N. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. Journal of Clinical Psychopharmacology 2000; 20: 150-58.[PubMed]
    69.Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 27-37.[PubMed]
    70.DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24: 4-10.[PubMed]
    71.Camidge R, Reigner B, Cassidy J, Grange S, Abt M, Weidekamm E, Jodrell D. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. Journal of Clinical Oncology 2005; 23: 4719-25.[PubMed]
    72.Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. British Journal of Clinical Pharmacology 1998; 46: 49-53.[PubMed]
    73.Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA. Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes. British Journal of Clinical Pharmacology 1996; 41: 344-46.[PubMed]
    74.Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology 1996; 51: 73-78.[PubMed]
    75.Szewczuk-Boguslawska M, Kiejna A, Grzesiak M, Beszlej JA, Chlebowska I, Orzechowska-Juzwenko K, Milejski P. The influence of clomipramine on CYP2D6 activity. Psychiatr Pol 2007; 41: 243-49.[PubMed]
    76.Ciraulo DA, Barnhill J, Boxenbaum H. Pharmacokinetic interaction of disulfiram and antidepressants. Am J Psychiat 1985; 142: 1373-74.[PubMed]
    77.Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: The role of gut CYP3A and P-glycoprotein. Life Sci 2002; 71: 1149-60.[PubMed]
    78.Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. British Journal of Clinical Pharmacology 2000; 49: 549-54.[PubMed]
    79.Sanz EJ, Bertilsson L. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Therapeutic Drug Monitoring 1990; 12: 297-99.[PubMed]
    80.Bauer LA, Horn JR, Maxon S, Easterling TR, Shen DD, Strandness DE. Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver flood flow and drug disposition. Journal of Clinical Pharmacology 2000; 40: 533-43.[PubMed]
    81.Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharmaceutics & Drug Disposition 2006; 27: 103-10.[PubMed]
    82.Wire MB, Shelton MJ, Studenberg S. Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical Pharmacokinetics 2006; 45: 137-68.[PubMed]
    83.Schellens JHM, Vanderwart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 638-45.[PubMed]
    84.Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology 1985; 19: 51-54.[PubMed]
    Disclaimer
    WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.